TY  - JOUR
AU  - Yaromina, Ala
AU  - Koi, Lydia
AU  - Schuitmaker, Lesley
AU  - van der Wiel, Alexander M A
AU  - Dubois, Ludwig J
AU  - Krause, Mechthild
AU  - Lambin, Philippe
TI  - Overcoming radioresistance with the hypoxia-activated prodrug CP-506: a pre-clinical study of local tumour control probability.
JO  - Radiotherapy and oncology
VL  - 186
SN  - 0167-8140
CY  - Amsterdam [u.a.]
PB  - Elsevier Science
M1  - DKFZ-2023-01180
SP  - 109738
PY  - 2023
N1  - Volume 186, September 2023, 109738
AB  - Tumour hypoxia is an established radioresistance factor. A novel hypoxia-activated prodrug CP-506 has been proven to selectively target hypoxic tumour cells and to cause anti-tumour activity. The current study investigates whether CP-506 improves outcome of radiotherapy in vivo.Mice bearing FaDu and UT-SCC-5 xenografts were randomized to receive 5 daily injections of CP-506/vehicle followed by single dose (SD) irradiation. In addition, CP-506 was combined once per week with fractionated irradiation (30 fractions/6 weeks). Animals were followed-up to score all recurrences. In parallel, tumours were harvested to evaluate pimonidazole hypoxia, DNA damage (γH2AX), expression of oxidoreductases.CP-506 treatment significantly increased local control rate after SD in FaDu, 62
KW  - Hypoxia (Other)
KW  - Hypoxia-activated prodrug CP-506 (Other)
KW  - Radiotherapy (Other)
KW  - local control (Other)
KW  - xenografts (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:37315579
DO  - DOI:10.1016/j.radonc.2023.109738
UR  - https://inrepo02.dkfz.de/record/276868
ER  -